SYH 2051
Alternative Names: SYH-2051Latest Information Update: 25 Sep 2025
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Antineoplastics
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Head and neck cancer; Solid tumours
- Clinical Phase Unknown Colorectal cancer; Gastrointestinal cancer
Most Recent Events
- 30 May 2025 Efficacy and adverse events data from clinical trial in Gastrointestinal cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 22 Jan 2025 CSPC Megalith Biopharmaceutical plans a phase I/II trial for Solid tumors (Late-stage disease, Monotherapy, Combination therapy, Metastatic disease, Inoperable/Unresectable) in January 2025 (IV) (NCT06775236)
- 15 Aug 2023 Phase-I clinical trials in Head and neck cancer (Late-stage disease) in China (PO) (NCT06011291)